New depression pill shows promise in Mid-Stage trial
NCT ID NCT07226661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new drug called SPN-821 can help adults with major depressive disorder who are already taking an antidepressant. About 230 participants will receive either SPN-821 or a placebo for 29 days. The main goal is to see if the drug reduces depression symptoms more than placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Collaborative Neuroscience Network
RECRUITINGGarden Grove, California, 92845, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can couples counseling lift depression in women?
- Brain wave clues: could inflammation markers forecast ECT outcomes?
- Can tailored brain zaps beat standard therapy for depression?
- Can a new daily pill lift the fog of depression?
- Can a new pill outsmart depression? a trial puts KH607 to the test
- Depression's biological fingerprint: a quest for objective diagnosis and personalized treatment